Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
LabGenius General Information
LabGenius has demonstrated the ability to rapidly design and test tens of thousands of novel antibody candidates using its AI-driven EVA™️ platform. The company’s lead molecules remain in preclinical development with no published clinical results yet. Their approach enables high-throughput functional screening in cell-based assays but has not advanced to IND or clinical stages as of early 2024.
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
M Ventures (investor/partner), Atomico (investor/partner), Obvious Ventures; no major pharma partnerships publicly announced.
LabGenius Funding
No funding data available
To view LabGenius's complete valuation and funding history, request access »